22nd Oct 2013 09:06
LONDON (Alliance News) - AstraZeneca PLC said Tuesday that it had initiated the third phase of its clinical programme for its advanced or metastatic non-small-cell lung cancer treatment Selumentinib.
The treatment is being investigated as second-line therapy for patients with tumours that are KRAS mutation-positive, which is present in 20% of human cancers and 20% to 30% of NSCLC tumours.
KRAS is a protein in humans that performs normal tissue signalling, and the mutation of this gene is key to the development of cancers.
Shares in the pharmaceutical company were trading down 9.50 pence at 3,165.50 pence Tuesday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca